Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? Does bortezomib inform our understanding of the immunology underlying neuromyelitis optica spectrum disorders?
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
American Medical Association)
2017
|